Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.47 -3.6%	$3.56	$2.45 ▼ $4.14	$275.38M	0.25	384,702 shs	235,252 shs
LFCR Lifecore Biomedical	$7.62 +1.2%	$7.63	$3.68 ▼ $8.85	$285.06M	0.65	212,511 shs	75,742 shs
NGNE Neurogene	$18.84 -4.3%	$20.36	$6.88 ▼ $74.49	$268.85M	1.69	223,279 shs	86,286 shs
STRO Sutro Biopharma	$0.90 -0.9%	$0.81	$0.52 ▼ $4.80	$75.91M	1.66	1.23 million shs	170,909 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-1.37%	+2.86%	-5.01%	+22.03%	-6.25%
LFCR Lifecore Biomedical	+0.40%	+4.01%	+2.73%	+9.93%	+58.86%
NGNE Neurogene	-1.65%	+0.41%	-9.18%	+5.07%	-45.21%
STRO Sutro Biopharma	+0.46%	+4.52%	+5.81%	+0.40%	-81.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.464 of 5 stars	3.3	0.0	0.0	3.3	2.5	1.3
LFCR Lifecore Biomedical	0.8675 of 5 stars	1.3	0.0	0.0	2.4	4.2	0.6
NGNE Neurogene	2.0046 of 5 stars	3.4	0.0	0.0	3.4	1.7	0.6
STRO Sutro Biopharma	4.2385 of 5 stars	3.1	5.0	4.7	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	72.91% Upside
LFCR Lifecore Biomedical	2.67	Moderate Buy	$8.00	4.99% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	145.05% Upside
STRO Sutro Biopharma	2.14	Hold	$4.47	398.85% Upside

Current Analyst Ratings Breakdown

Latest STRO, AVIR, NGNE, and LFCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $3.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
LFCR Lifecore Biomedical	$128.87M	2.21	N/A	N/A	$0.04 per share	190.50
NGNE Neurogene	$930K	289.08	N/A	N/A	$19.15 per share	0.98
STRO Sutro Biopharma	$104.47M	0.73	N/A	N/A	($0.38) per share	-2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.31	N/A	N/A	N/A	N/A	-33.33%	-30.34%	N/A
STRO Sutro Biopharma	-$227.46M	-$2.53	N/A	N/A	N/A	-201.32%	-852.70%	-58.67%	11/12/2025 (Estimated)

Latest STRO, AVIR, NGNE, and LFCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	NGNE Neurogene	-$1.15	-$1.05	+$0.10	-$1.05	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
8/7/2025	Q2 2025	STRO Sutro Biopharma	-$0.39	-$0.14	+$0.25	-$0.14	$14.55 million	$63.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
LFCR Lifecore Biomedical	113.76	2.84	1.77
NGNE Neurogene	N/A	18.07	18.07
STRO Sutro Biopharma	N/A	3.12	3.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
LFCR Lifecore Biomedical	83.36%
NGNE Neurogene	52.37%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
LFCR Lifecore Biomedical	32.20%
NGNE Neurogene	11.64%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable
NGNE Neurogene	90	14.27 million	12.61 million	Optionable
STRO Sutro Biopharma	240	84.77 million	81.72 million	Optionable

STRO, AVIR, NGNE, and LFCR Headlines

Recent News About These Companies

Affinity Asset Advisors LLC Makes New Investment in Sutro Biopharma, Inc. $STRO

August 28 at 9:09 AM | marketbeat.com

Wall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to Sell

August 25 at 2:44 AM | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Rating Lowered to Sell at Wall Street Zen

August 24, 2025 | americanbankingnews.com

Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers

August 20, 2025 | msn.com

Sutro Biopharma (STRO) Gets a Buy from Truist Financial

August 14, 2025 | theglobeandmail.com

Wells Fargo & Company Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $3.00

August 13, 2025 | marketbeat.com

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

August 12, 2025 | msn.com

Sutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street Zen

August 10, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)

August 9, 2025 | theglobeandmail.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 8, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 7, 2025 | globenewswire.com

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts

August 5, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Trading 0.6% Higher - Time to Buy?

August 3, 2025 | marketbeat.com

Sutro Biopharma, Inc.: Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 24, 2025 | finanznachrichten.de

Here's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash Wisely

July 23, 2025 | finance.yahoo.com

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 23, 2025 | finance.yahoo.com

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

June 16, 2025 | msn.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STRO, AVIR, NGNE, and LFCR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.47 -0.13 (-3.61%)

Closing price 04:00 PM Eastern

Extended Trading

$3.60 +0.13 (+3.60%)

As of 05:08 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.62 +0.09 (+1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$7.61 -0.01 (-0.13%)

As of 04:11 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Neurogene NASDAQ:NGNE

$18.84 -0.85 (-4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$18.90 +0.05 (+0.29%)

As of 04:33 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sutro Biopharma NASDAQ:STRO

$0.90 -0.01 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$0.90 +0.00 (+0.29%)

As of 04:14 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time